Stony Brook (N.Y.) Heart Institute became the first center globally to administer a commercial dose of plozasiran, a newly approved RNA-interference therapy for familial chylomicronemia syndrome.
The Center for Advanced Lipid Management delivered the therapy within days of FDA approval, according to a Dec. 30 news release.
Plozasiran targets apolipoprotein C-III and, in phase 3 trials, significantly reduced triglyceride levels and pancreatitis episodes in patients with familial chylomicronemia syndrome, a rare genetic disorder that prevents the body from properly breaking down dietary fats. The syndrome affects an estimated 6,500 people in the U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
